What is Keros Therapeutics Inc?
, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 217.44M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 51,700 shares $18k | 0 |
| 3-6months | 818,253 shares $191k | 33,000 shares $31k |
| 6-9months | 0 | 34,000 shares $45k |
| 9-12months | 17,015 shares $113k | 0 |